RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Shanghai

上海 乳腺癌

All diseases in Shanghai

19 hospitals in Shanghai

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shanghai may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 390 papers led
  2. 115 papers led
  3. 76 papers led
  4. 62 papers led
    No open trial led
  5. 50 papers led
    No open trial led
  6. 44 papers led
    No open trial led
  7. 44 papers led
  8. 43 papers led
    No open trial led
  9. 36 papers led
    No open trial led
  10. 28 papers led
    No open trial led
  11. 27 papers led
    No open trial led
  12. 26 papers led
    No open trial led
  13. 26 papers led
  14. 17 papers led
    No open trial led
  15. 10 papers led
  16. 10 papers led
    No open trial led
  17. 1 paper led
    No open trial led
  18. 1 paper led
  19. 0 papers led

Breast cancer in every city Shanghai on the disease page, with the national map

217

open trials on breast cancer with a hospital in Shanghai

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shanghai as lead sponsor or study site. 135 of them are led by a hospital in Shanghai. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT06889610

    Age 18 years to 80 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  2. Recruiting
    Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT06993506

    Age 18 years to Not stated (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou

  3. Recruiting
    Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07235176

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  4. Recruiting
    Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07283692

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  5. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  6. Recruiting
    A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07349069

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  7. Recruiting
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07383818

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an

  8. Recruiting
    Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07393425

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  9. Recruiting
    Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07396324

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  10. Recruiting
    RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07413939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan

  11. Recruiting
    CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07432178

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  12. Recruiting
    A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07441460

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  13. Recruiting
    YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07461454

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  14. Recruiting
    Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07471776

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  15. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  16. Recruiting
    Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07498478

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan

  17. Recruiting
    Ultra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer
    Phase
    N/A
    Started
    2026-04
    Posted
    Registry
    NCT07527689

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  18. Recruiting
    Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07528716

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  19. Recruiting
    Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07541664

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  20. Recruiting
    Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07551050

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  21. Recruiting
    Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07557654

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  22. Recruiting
    Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07581795

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  23. Recruiting
    A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07591090

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  24. Recruiting
    Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07623577

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  25. Recruiting
    Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07638852

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  26. Recruiting
    Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07647016

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  27. Recruiting
    A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07647029

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  28. Recruiting
    A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07658183

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  29. Recruiting
    A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07729956

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  30. Recruiting
    Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
    Phase
    Phase 3
    Started
    2026-07
    Posted
    Registry
    NCT07797218

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  31. Recruiting
    Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07829848

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  32. Recruiting
    1-Week Versus 3-Week PBI
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07832279

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  33. Recruiting
    Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction
    Phase
    N/A
    Started
    2026-10
    Posted
    Registry
    NCT07835139

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  34. Recruiting
    Artificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast Cancer
    Phase
    N/A
    Started
    2026-07
    Posted
    Registry
    NCT07844941

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  35. Recruiting
    Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06637150

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  36. Recruiting
    Reverse HER2-negative Immune Resistant Breast Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06731140

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  37. Recruiting
    BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06756932

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou

  38. Recruiting
    HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Posted
    Registry
    NCT06769425

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  39. Recruiting
    Capecitabine in Low Risk Triple Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06787339

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  40. Recruiting
    BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06793332

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  41. Recruiting
    A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06827236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an

  42. Recruiting
    A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06830889

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  43. Recruiting
    A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
    Phase
    Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06832202

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  44. Recruiting
    JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06846437

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  45. Recruiting
    A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
    Phase
    N/A
    Started
    2025-02
    Posted
    Registry
    NCT06856200

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital, Fudan UniversityShanghai

  46. Recruiting
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06889688

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Guiyang, Shanghai, Wuhan

  47. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  48. Recruiting
    Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06942234

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  49. Recruiting
    A Real World Study of Sacituzumab Govitecan
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06966141

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  50. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  51. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06977893

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou

  52. Recruiting
    A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06992882

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  53. Recruiting
    Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06993844

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Shanghai

  54. Recruiting
    A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07002177

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  55. Recruiting
    A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07003074

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan

  56. Recruiting
    Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07008976

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou

  57. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  58. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  59. Recruiting
    SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07080619

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  60. Recruiting
    A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07100106

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Jinan, Nanning, Shanghai, Tianjin

  61. Recruiting
    A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07111832

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

  62. Recruiting
    An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07117630

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  63. Recruiting
    A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07130383

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  64. Recruiting
    Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT07134153

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  65. Recruiting
    T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07150208

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  66. Recruiting
    T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07152782

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  67. Recruiting
    Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07156253

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  68. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  69. Recruiting
    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07174336

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan

  70. Recruiting
    Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07180056

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  71. Recruiting
    Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07180082

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  72. Recruiting
    Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07180160

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  73. Recruiting
    Trastuzumab Deruxtecan in Advanced Breast Cancer
    Phase
    Not given
    Started
    2025-08
    Posted
    Registry
    NCT07180264

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  74. Recruiting
    SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07182721

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  75. Recruiting
    A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
    Phase
    Phase 1
    Started
    2025-10
    Posted
    Registry
    NCT07213791

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  76. Recruiting
    An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07222267

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen

  77. Recruiting
    Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07351487

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Hefei, Shanghai

  78. Recruiting
    Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT07362914

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  79. Recruiting
    Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07371208

    Age 18 years to 65 years (registered criteria)

    Led by Ruijin HospitalShanghai

  80. Recruiting
    ctDNA-guided Treatment Decision-making
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07394218

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  81. Recruiting
    AI-Enhanced Imaging in Population Breast Cancer Screening
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT07411443

    Age 35 years to 69 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  82. Recruiting
    Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07469267

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan

  83. Recruiting
    Robustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation
    Phase
    Not given
    Started
    2025-10
    Posted
    Registry
    NCT07498855

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  84. Recruiting
    Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT07574749

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  85. Recruiting
    A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
    Phase
    Phase 4
    Started
    2025-08
    Posted
    Registry
    NCT07578064

    Age 18 years to 80 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  86. Recruiting
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07612891

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  87. Recruiting
    A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
    Phase
    Not given
    Started
    2025-06
    Posted
    Registry
    NCT07653893

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  88. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  89. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  90. Recruiting
    Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
    Phase
    Phase 4
    Started
    2024-01
    Posted
    Registry
    NCT06230055

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  91. Recruiting
    Dalpiciclib in HR+/HER2- ABC
    Phase
    Not given
    Started
    2024-05
    Posted
    Registry
    NCT06301438

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  92. Recruiting
    DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06313086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  93. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  94. Recruiting
    A Study of GC203 TIL in Advanced Malignant Solid Tumors
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06375187

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  95. Recruiting
    LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06387628

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  96. Recruiting
    clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
    Phase
    Not given
    Started
    2024-03
    Posted
    Registry
    NCT06392217

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  97. Recruiting
    Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06404697

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  98. Recruiting
    A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06439771

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  99. Recruiting
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06452706

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an

  100. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  101. Recruiting
    A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06471205

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  102. Recruiting
    A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06492005

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  103. Recruiting
    A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06493864

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  104. Recruiting
    Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06500208

    Age 18 years to 65 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  105. Recruiting
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06503783

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  106. Recruiting
    Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06516289

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  107. Recruiting
    A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06555068

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  108. Recruiting
    68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
    Phase
    Not given
    Started
    2024-08
    Posted
    Registry
    NCT06559371

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  109. Recruiting
    A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06567353

    Age 18 years to 75 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  110. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06611813

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 6 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Urumqi, Zhengzhou

  111. Recruiting
    AI-Assisted Non-Contrast CT for Multi-Cancer Screening
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT06632886

    Age 18 years to Not stated (registered criteria)

    Led by Changhai HospitalShanghai

  112. Recruiting
    All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer:a Multi-center, Multi-cohort Phase II Trial
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06636981

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  113. Recruiting
    Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06649331

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  114. Recruiting
    Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2024-11
    Posted
    Registry
    NCT06666270

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou

  115. Recruiting
    A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06677879

    Age 18 years to 80 years; women only (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  116. Recruiting
    Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06682195

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou

  117. Recruiting
    Target-specific immunoPET Imaging of Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06715826

    Age 18 years to 75 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  118. Recruiting
    The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06718010

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  119. Recruiting
    GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06725940

    Age 18 years to 65 years (registered criteria)

    Led by Ruijin HospitalShanghai

  120. Recruiting
    QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06786026

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  121. Recruiting
    Safety and Efficacy of IMPT or IMRT for Breast Cancer
    Phase
    Not given
    Started
    2024-12
    Posted
    Registry
    NCT06826885

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin HospitalShanghai

  122. Recruiting
    Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
    Phase
    N/A
    Started
    2024-01
    Posted
    Registry
    NCT06911528

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  123. Recruiting
    Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06950086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  124. Recruiting
    Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
    Phase
    N/A
    Started
    2024-10
    Posted
    Registry
    NCT07135661

    Age 40 years to Not stated; women only (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  125. Recruiting
    ctDNA in HER2+ EBC Neoadjuvant Treatment
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT07335081

    Age 18 years to 70 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  126. Recruiting
    A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Posted
    Registry
    NCT07923214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai

  127. Recruiting
    Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
    Phase
    N/A
    Started
    2023-01
    Posted
    Registry
    NCT04960839

    Age 30 years to 70 years; women only (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 5 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  128. Recruiting
    A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
    Phase
    Phase 2
    Started
    2023-01
    Posted
    Registry
    NCT05692674

    Age 18 years to 80 years; women only (registered criteria)

    Led by Shanghai Proton and Heavy Ion CenterShanghai

  129. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  130. Recruiting
    FUSCC Refractory TNBC Platform Study (FUTURE2.0)
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05749588

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  131. Recruiting
    PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05759546

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  132. Recruiting
    Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
    Phase
    Phase 3
    Started
    2023-03
    Posted
    Registry
    NCT05760378

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  133. Recruiting
    CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
    Phase
    Not given
    Started
    2023-04
    Posted
    Registry
    NCT05795335

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  134. Recruiting
    Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-04
    Posted
    Registry
    NCT05806060

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  135. Recruiting
    RC48-ADC in HER2-low Advanced Breast Cancer
    Phase
    N/A
    Started
    2023-05
    Posted
    Registry
    NCT05831878

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  136. Recruiting
    Disitamab Vedotin (RC48-ADC) in Breast Cancer
    Phase
    Not given
    Started
    2023-06
    Posted
    Registry
    NCT05851677

    Age not stated (registered criteria)

    Led by Renji HospitalShanghai

  137. Recruiting
    Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
    Phase
    Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05861271

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  138. Recruiting
    A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05862064

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  139. Recruiting
    Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
    Phase
    N/A
    Started
    2023-06
    Posted
    Registry
    NCT05876065

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  140. Recruiting
    EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05883852

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  141. Recruiting
    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05891093

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  142. Recruiting
    Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT05891561

    Age 18 years to 75 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  143. Recruiting
    TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05901428

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  144. Recruiting
    Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05909332

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  145. Recruiting
    Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05910398

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  146. Recruiting
    Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT05949541

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  147. Recruiting
    Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT05950945

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou

  148. Recruiting
    Regional Lymph Node Irradiation for High-risk pN0 Breast Cancer
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT05976412

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  149. Recruiting
    A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
    Phase
    Phase 3
    Started
    2023-08
    Posted
    Registry
    NCT05999149

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  150. Recruiting
    A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06042894

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  151. Recruiting
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06064812

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  152. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  153. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  154. Recruiting
    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06120283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang

  155. Recruiting
    DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06178159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  156. Recruiting
    Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
    Phase
    Phase 2
    Started
    2023-07
    Posted
    Registry
    NCT06227117

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Tianjin

  157. Recruiting
    The Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
    Phase
    N/A
    Started
    2023-03
    Posted
    Registry
    NCT07638774

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  158. Recruiting
    Reverse Triple Negative Immune Resistant Breast Cancer
    Phase
    Phase 2
    Started
    2022-06
    Posted
    Registry
    NCT05076682

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  159. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Posted
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  160. Recruiting
    CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
    Phase
    N/A
    Started
    2022-09
    Posted
    Registry
    NCT05360290

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  161. Recruiting
    A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05470348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  162. Recruiting
    Patient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
    Phase
    N/A
    Started
    2022-08
    Posted
    Registry
    NCT05512286

    Age 18 years to Not stated; women only (registered criteria)

    Led by Huashan Hospital; 2 listed hospitals as study sitesChangsha, Shanghai, Zhengzhou

  163. Recruiting
    GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT05575804

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  164. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  165. Recruiting
    Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05582499

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  166. Recruiting
    SNF Platform Study of HR+/ HER2-advanced Breast Cancer
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05594095

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  167. Recruiting
    Pre-operative Therapy in Breast Cancer
    Phase
    Not given
    Started
    2022-11
    Posted
    Registry
    NCT05621564

    Age 18 years to Not stated; women only (registered criteria)

    Led by Renji HospitalShanghai

  168. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  169. Recruiting
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    Phase
    Not given
    Started
    2022-10
    Posted
    Registry
    NCT06551220

    Age 18 years to 80 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai

  170. Recruiting
    Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer
    Phase
    N/A
    Started
    2021-03
    Posted
    Registry
    NCT04517266

    Age 18 years to 80 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  171. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  172. Recruiting
    Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2021-01
    Posted
    Registry
    NCT04947280

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  173. Recruiting
    The Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
    Phase
    Not given
    Started
    2021-01
    Posted
    Registry
    NCT05032768

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  174. Recruiting
    Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
    Phase
    Phase 3
    Started
    2021-09
    Posted
    Registry
    NCT05059379

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  175. Recruiting
    A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
    Phase
    Early phase 1
    Started
    2021-11
    Posted
    Registry
    NCT05142475

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  176. Recruiting
    Neoadjuvant Radiation in Locally Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2021-03
    Posted
    Registry
    NCT05479409

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  177. Recruiting
    Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer
    Phase
    N/A
    Started
    2021-08
    Posted
    Registry
    NCT07776301

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  178. Recruiting
    Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
    Phase
    N/A
    Started
    2020-04
    Posted
    Registry
    NCT04281641

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  179. Recruiting
    Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment
    Phase
    Phase 3
    Started
    2019-02
    Posted
    Registry
    NCT03829553

    Age 18 years to 75 years; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  180. Recruiting
    Sentinel Node Biopsy Vs Observation After Axillary PET
    Phase
    N/A
    Started
    2019-09
    Posted
    Registry
    NCT04072653

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  181. Recruiting
    Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
    Phase
    Phase 3
    Started
    2019-12
    Posted
    Registry
    NCT04254263

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  182. Recruiting
    Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery
    Phase
    N/A
    Started
    2018-07
    Posted
    Registry
    NCT04025164

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesDalian, Guiyang, Shanghai

  183. Recruiting
    Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
    Phase
    Phase 3
    Started
    2017-07
    Posted
    Registry
    NCT03201861

    Age 18 years to 70 years; women only (registered criteria)

    Led by Renji HospitalShanghai

  184. Recruiting
    Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
    Phase
    Phase 2
    Started
    2017-08
    Posted
    Registry
    NCT03392233

    Age 18 years to 85 years (registered criteria)

    Led by Renji HospitalShanghai

  185. Recruiting
    A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
    Phase
    Phase 1
    Started
    2013-01
    Posted
    Registry
    NCT02897700

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  186. Not yet recruiting
    Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
    Phase
    Phase 2
    Started
    2027-01
    Posted
    Registry
    NCT07419880

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  187. Not yet recruiting
    JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07336771

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  188. Not yet recruiting
    Huaier Granule and Proteinuria
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07355361

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  189. Not yet recruiting
    Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
    Phase
    Phase 3
    Started
    2026-02
    Posted
    Registry
    NCT07382687

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  190. Not yet recruiting
    Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07410559

    Age 18 years to 75 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  191. Not yet recruiting
    A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07419867

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  192. Not yet recruiting
    ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07423611

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  193. Not yet recruiting
    Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
    Phase
    Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07466927

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  194. Not yet recruiting
    Proton vs Photon IMRT Toxicity in Breast Cancer
    Phase
    Not given
    Started
    2026-04
    Posted
    Registry
    NCT07537712

    Age 18 years to Not stated; women only (registered criteria)

    Led by Ruijin HospitalShanghai

  195. Not yet recruiting
    A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07556848

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  196. Not yet recruiting
    Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07628504

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  197. Not yet recruiting
    Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07771881

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  198. Not yet recruiting
    A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
    Phase
    N/A
    Started
    2026-09
    Posted
    Registry
    NCT07782086

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou

  199. Not yet recruiting
    Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07825753

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  200. Not yet recruiting
    SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07856303

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  201. Not yet recruiting
    Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules
    Phase
    Phase 4
    Started
    2025-09
    Posted
    Registry
    NCT05871437

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  202. Not yet recruiting
    Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06797622

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  203. Not yet recruiting
    Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT06798506

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  204. Not yet recruiting
    Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT06965556

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  205. Not yet recruiting
    Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06996093

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  206. Not yet recruiting
    A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07036185

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  207. Not yet recruiting
    Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07088588

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  208. Not yet recruiting
    De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07153757

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  209. Not yet recruiting
    Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07169864

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  210. Not yet recruiting
    Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06510465

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  211. Not yet recruiting
    T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
    Phase
    Phase 2
    Started
    2024-09
    Posted
    Registry
    NCT06548178

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  212. Not yet recruiting
    A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06724263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  213. Not yet recruiting
    JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06731153

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  214. Not yet recruiting
    Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
    Phase
    Phase 4
    Started
    2023-10
    Posted
    Registry
    NCT05860907

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou

  215. Enrolling by invitation
    Breast Cancer PET/CT Imaging With 68Ga-pAKTi
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06943313

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  216. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

  217. Enrolling by invitation
    Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07798466

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Shanghai

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Shanghai, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Cancer Hospital, Fudan Universitynonenonenonenonenonenone01 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Changhai Hospital海军军医大学第一附属医院(长海医院)2221 open19315 open201 open8812 open101 open7none2none110nonenonenonenonenone9nonenonenonenonenonenone01 opennonenonenonenone417none1none2nonenonenonenonenonenone1none1nonenonenone1none001none0nonenonenonenone
Changzheng Hospital海军军医大学第二附属医院(长征医院)none3151 open171 open4041 opennone10nonenone516402262 opennonenonenone6nonenonenone1nonenonenonenonenonenonenone5none81nonenone2none0nonenonenonenone1none5nonenone21nonenonenonenonenone1nonenonenonenone
Child Health Hospitalnonenonenonenonenonenone26nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone8nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children Hospital, Fudan Universitynonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital of Fudan University复旦大学附属儿科医院nonenonenonenonenonenonenone115004none111none0none0501 opennone1nonenonenonenone12none213 open5372 open310nonenonenonenone311 open021021none1none1042none0none10none
Dahua Hospitalnonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
East Hospital上海市东方医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Eastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院)nonenone2144 open6none7nonenonenonenonenone41nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone00nonenonenonenonenonenonenonenonenone
Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院324 opennonenonenonenonenonenonenonenone63 open0nonenone51 opennonenonenonenonenone161 opennonenonenonenonenonenonenonenonenonenonenonenone17nonenone0nonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenone
Fengxian District Central Hospital上海市奉贤区中心医院none3nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fifth People's Hospital of Fudan University复旦大学附属上海市第五人民医院nonenonenonenonenone2nonenonenonenone11nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Naval Medical Universitynonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Rehabilitation Hospital, Tongji University上海市第一康复医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院381 open328 open542 open8817 open24331 open21211 open39090 open15nonenone360none4none0nonenone3318 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Gongli Hospital上海市浦东新区公利医院nonenonenonenonenonenonenonenonenonenonenone00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Guangming Traditional Chinese Medicine Hospital上海市浦东新区光明中医医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Gynecology Hospital, Fudan University复旦大学附属妇产科医院nonenonenonenonenonenone17nonenonenonenone0none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Health Sciences Affiliated Zhoupu Hospital上海市浦东新区周浦医院nonenonenonenonenonenonenonenonenonenonenone111nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Huadong Hospital, Fudan University复旦大学附属华东医院none11 opennone41 open42111 opennonenonenonenonenone0nonenonenonenonenonenone06nonenonenonenonenonenonenonenone2nonenone14nonenonenonenonenone0none0nonenonenonenone24none1nonenonenonenonenone1nonenonenonenonenonenonenonenone
Huashan Hospital复旦大学附属华山医院none12621 open226 open62191 open261 open1226 opennonenone420105nonenonenone351 opennone1nonenonenone231 open0314 open17nonenone53none1nonenone7none1011none111none6nonenonenone00nonenone21nonenonenonenonenone
Infant Hospital上海市第一妇婴保健院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone30nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiading District Anting Hospital上海市嘉定区安亭医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jiahui International Hospital上海嘉会国际医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jing'an District Centre Hospital上海市静安区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Jinshan Hospital, Fudan University复旦大学附属金山医院nonenonenonenonenonenonenonenonenonenonenone5none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone
Longhua Hospital上海中医药大学附属龙华医院none7111344none36nonenonenone14none1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenone51 opennone2nonenonenone1nonenonenonenonenonenonenonenone1nonenonenone20nonenonenonenone1nonenonenonenone
Minhang Hospital上海市闵行区中心医院nonenonenone9nonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Putuo Hospital上海市普陀区中心医院nonenonenonenonenonenonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Renji Hospital上海交通大学医学院附属仁济医院22 open81 open1045 open655 open883 open1037 open7620 open251 open3113102none242 opennonenone3232 opennonenone1nonenone111 open231 opennonenone31110020none0none3none1none02none6nonenonenone171 open5nonenonenone2nonenonenonenonenone
Ruijin Hospital上海交通大学医学院附属瑞金医院none221 open353 open9613 open6811 open11418 open11518 open14nonenonenone131 open22022114 opennone29755 open05none0nonenonenonenone2nonenone594 open211nonenone02203nonenonenone142 opennonenonenone0nonenonenonenonenone2nonenonenonenone
Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine上海市第七人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Baoshan Luodian Hospital上海市宝山区罗店医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Chest Hospital上海市胸科医院none4012 opennonenone41445 opennonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone114nonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Children's Hospital上海市儿童医院nonenonenonenonenonenonenonenonenonenonenone1none61none1none1none40nonenonenonenonenonenonenonenone1none102nonenonenonenonenonenonenonenonenone20000nonenonenonenone2nonenonenonenonenonenonenonenone
Shanghai Children's Medical Center上海交通大学医学院附属上海儿童医学中心nonenonenonenonenonenonenonenone171 opennonenone0none110none81 open5none110nonenonenone2nonenonenonenonenonenonenone971 open2nonenonenonenonenonenone00002 opennonenone30nonenonenonenone221nonenonenonenonenonenone
Shanghai East Hospital, Tongji University同济大学附属东方医院1133637502 open125013none01222113nonenonenone7nonenonenonenone1nonenonenonenonenonenone201 open11nonenonenonenone4none11 opennonenonenonenonenonenone1nonenonenone0nonenonenonenonenonenonenonenonenonenone
Shanghai Eighth People Hospital上海市第八人民医院nonenonenonenonenonenonenonenonenone1none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Electric Power Hospital上海电力医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Fengxian District Central Hospitalnonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Fourth People's Hospital同济大学附属上海市第四人民医院nonenonenonenonenonenonenonenone1nonenone1nonenonenone31 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai General Hospital上海市第一人民医院53361 open271 open494 open357 open6213none152420none200none118 opennone0nonenonenonenonenonenonenonenonenone254none11none1none1nonenonenonenonenonenone0nonenonenonenone0nonenonenonenonenone2nonenonenone
Shanghai Jiading Central Hospital上海市嘉定区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Shanghai Mengchao Cancer Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Mental Health Center上海市精神卫生中心nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Municipal Hospital, Shanghai University of Traditional Chinese Medicine上海市中医医院nonenonenonenone28nonenonenonenonenonenone2none10nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenone11nonenonenonenonenonenonenonenonenone
Shanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院54nonenone3311279none29none1512nonenonenonenonenone221 opennone1nonenone1nonenonenonenonenonenone1502none0none4nonenone0nonenone11none0nonenone10nonenone01nonenone1nonenonenone
Shanghai Proton and Heavy Ion Center上海市质子重离子医院0none2none63 open01 open13 open2nonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pudong Hospital上海市浦东医院nonenonenonenonenone2106none0none0nonenonenone10nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pudong New Area People's Hospital上海市浦东新区人民医院nonenonenonenonenonenonenonenonenonenonenone0none00nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Pulmonary Hospital上海市肺科医院none5nonenone39443 opennonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone71 opennonenonenonenonenonenone0none1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Putuo District Liqun Hospital上海市普陀区利群医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Sixth People's Hospital上海市第六人民医院3027214315438nonenone0350411nonenonenonenonenonenonenonenonenone2nonenonenonenonenone112nonenonenonenone2none4nonenonenone0none00nonenone711nonenonenonenone0nonenonenonenone
Shanghai Songjiang District Central Hospital上海市松江区中心医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Stomatological Hospital上海市口腔医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Tenth People's Hospital上海市第十人民医院none32721611444123none0210205nonenonenone10nonenonenonenonenonenonenonenonenonenonenone27nonenonenone2none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Tong Ren Hospital上海市同仁医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shanghai Xuhui Central Hospital上海徐汇中心医院nonenonenonenonenonenonenonenone1nonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenone
Shibei Hospital上海市静安区市北医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shuguang Hospital上海中医药大学附属曙光医院nonenone20nonenonenonenonenonenonenonenone1none00nonenonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenone2nonenonenone3nonenonenonenonenonenonenonenone3nonenonenone11nonenonenonenonenonenonenonenonenone
Tongji Hospital同济大学附属同济医院none3none1730nonenone9nonenonenone212none21 open01 open0none185 opennonenonenonenonenonenonenonenonenonenonenone92nonenonenonenone2none0nonenonenonenone0none0nonenonenonenone0nonenonenonenonenonenonenonenonenone
Xinhua Hospital上海交通大学医学院附属新华医院nonenone21243212283215none401702nonenonenone7nonenonenonenonenonenonenone2none297363 open330nonenone0none10100001 open221 open1010364nonenonenonenonenonenone
Xinshijie Zhongxing Eye Hospital上海新视界中兴眼科医院nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yangpu Hospital上海市杨浦区中心医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yangzhi Rehabilitation Hospital, Tongji University上海市养志康复医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Yueyang Hospital, Shanghai University of Traditional Chinese Medicine上海中医药大学附属岳阳中西医结合医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone1nonenonenonenone1nonenonenonenone
Zhabei Central Hospital上海市静安区闸北中心医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenone7nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Zhongshan Hospital, Fudan University复旦大学附属中山医院3568 open40816 open1348 open1864 open779 open441 open193none052802234 opennonenonenone142 open1nonenonenonenone0411 opennonenonenone10914 open30none0332 opennone313nonenonenone12none4nonenone10nonenonenone1none0nonenonenonenone
Zhongshan-Xuhui Hospital上海市徐汇区中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Shanghai.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shanghai on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data